The context of this Discussion is the apparent clash of profit versus ethics relating to critical types of intellectual property (IP). The dilemma is to what extent should businesses prioritize profit and the promotion of innovation through IP protection over advancing the greater good for social welfare and sustainability (people and planet).
Scenario
Imagine X5RL, a pharmaceutical company, develops a groundbreaking, patented treatment for a widespread chronic disease. X5RL sets a high price on the treatment to recover its R&D costs, fund future innovations, and reap profits. However, many patients – especially in low-income regions — cannot afford the treatment due to lack of – or insufficient – insurance coverage. As a result, a significant measure of the population is foreclosed from the lifesaving treatment.
Discuss!
Post a cohesive, substantive paragraph that incorporates the following ; (do NOT list as a “Q & A”):
Is the public’s financial issue X5RL’s problem? Should it be?
How can this company integrate CSR principles into its strategy to profit from its IP and also provide equitable access, and what ethical considerations should guide this approach?
(HINT: Compare GSK and insulin producers in developing your thoughts).
Jamali, H. R. (2024). Navigating intellectual property (IP): A comparative analysis of Australian universities’ IP policies. PLoS One, 19(5)https://doi.org/10.1371/journal.pone.0304647
This business-ethics discussion asks you to weigh profit and innovation (protected by IP) against equitable access to a lifesaving, patented drug. Write it as one cohesive, substantive paragraph — not a Q&A — that works through access responsibility, CSR, and the GSK/insulin comparison.
Key takeaways
- Frame the real tension: IP incentivizes innovation but can price out patients who need the treatment.
- Engage whether access is X5RL’s problem — argue it with ethics, not just law.
- Show how CSR can reconcile profit with equitable access (tiered pricing, licensing, access programs).
- Use the GSK vs. insulin-producer comparison as evidence.
- Write as a cohesive paragraph and cite your source (Jamali, 2024).
Frame the dilemma
Patents reward R&D and fund future innovation, but a high price can foreclose lifesaving treatment for low-income patients. That’s the profit-versus-social-welfare clash at the heart of the prompt — state it clearly before arguing.
Is access X5RL’s problem?
Legally, the company owns the IP and sets the price. Ethically, there’s a strong case that a firm holding a monopoly on a lifesaving good bears some responsibility for access — through stakeholder theory and corporate social responsibility, not just shareholder returns. Take a reasoned position.
Integrating CSR with IP profits
Show how the company can do both: tiered/differential pricing by region and income, voluntary licensing or patent pools for generics in low-income markets, patient assistance programs, and partnerships with NGOs or governments. These protect innovation incentives while widening access — and can build brand trust and long-term value.
Use the GSK / insulin comparison
Contrast approaches: GSK’s record on tiered pricing and access initiatives versus the criticism of insulin producers for pricing that put a century-old essential drug out of reach. The comparison grounds your argument in real outcomes.
Format
Deliver it as one cohesive, substantive paragraph (not a list), weaving the points together, and cite Jamali (2024) and any other sources in your required style.